Indeterminate Thyroid Nodules in the Era of Molecular Genomics

Overview

Journal Mol Genet Genomic Med

Specialty Genetics

Date 2020 May 22

PMID 32436637

Citations 8

Authors

Sarika N Rao

Victor Bernet

Affiliations

Soon will be listed here.

Abstract

Background: Indeterminate thyroid nodules are diagnosed in up to 30% of fine-needle aspirations and the risk of malignancy in these cases are highly variable. Consequently, managing these nodules has been a challenge. While a diagnostic thyroidectomy would help clarify the pathology, there is the risk of developing surgical-related complications for a procedure that may not have been necessary and associated high costs. Genomic testing of indeterminate thyroid nodules may help better guide management.

Methods: We present an unbiased comprehensive review of available molecular testing for classifying indeterminate thyroid nodules, as well as their strengths and limitations, with the objective to allow practitioners to choose the best testing modality for their patients.

Results: Molecular testing of these nodules provided a platform to help distinguish benign versus malignant nodules, providing more confidence to rule in or rule out the likelihood of thyroid cancer in indeterminate nodules.

Conclusion: Genomic testing has evolved to more comprehensive panels to better stratify indeterminate nodules, including Hürthle cell neoplasms and noninvasive follicular neoplasm with papillary-like nuclear features. Understanding the methodology of each available test improves patient care and reduces unnecessary costs.

Citing Articles

Thermal ablation for Bethesda III and IV thyroid nodules: current diagnosis and management.

Chan W, Chiang P, Lin A, Chang Y, Lin W Ultrasonography. 2024; 43(6):395-406.

PMID: 39397446 PMC: 11532522. DOI: 10.14366/usg.24083.

Surgical Management of Indeterminate Thyroid Nodules across Different World Regions: Results from a Retrospective Multicentric (the MAIN-NODE) Study.

Canu G, Cappellacci F, Abdallah A, Elzahaby I, Figueroa-Bohorquez D, Lori E Cancers (Basel). 2023; 15(15).

PMID: 37568811 PMC: 10416924. DOI: 10.3390/cancers15153996.

A Review of Evidence for the Involvement of the Circadian Clock Genes into Malignant Transformation of Thyroid Tissue.

Putilov A, Budkevich E, Budkevich R Clocks Sleep. 2023; 5(3):384-398.

PMID: 37489438 PMC: 10366820. DOI: 10.3390/clockssleep5030029.

An innovative synthetic support for immunocytochemical assessment of cytologically indeterminate (Bethesda III) thyroid nodules.

Taccogna S, Papini E, Novizio R, DAngelo M, Turrini L, Persichetti A Front Endocrinol (Lausanne). 2022; 13:1078019.

PMID: 36531453 PMC: 9752034. DOI: 10.3389/fendo.2022.1078019.

Prospects of Testing Diurnal Profiles of Expressions of TSH-R and Circadian Clock Genes in Thyrocytes for Identification of Preoperative Biomarkers for Thyroid Carcinoma.

Putilov A Int J Mol Sci. 2022; 23(20).

PMID: 36293065 PMC: 9603503. DOI: 10.3390/ijms232012208.

References

Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf J, Shah R . Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016; 126(3):1052-66. PMC: 4767360. DOI: 10.1172/JCI85271. View

Alexander E, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F . Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab. 2013; 99(1):119-25. DOI: 10.1210/jc.2013-2482. View

Taye A, Gurciullo D, Miles B, Gupta A, Owen R, Inabnet 3rd W . Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules. Surgery. 2017; 163(1):97-103. DOI: 10.1016/j.surg.2017.07.032. View

Rivas A, Nassar A, Zhang J, Casler J, Chindris A, Smallridge R . ThyroSeqV2.0 Molecular Testing: A Cost-Effective Approach for the Evaluation of Indeterminate Thyroid Nodules. Endocr Pract. 2018; 24(9):780-788. DOI: 10.4158/EP-2018-0212. View

Kimura E, Nikiforova M, Zhu Z, Knauf J, Nikiforov Y, Fagin J . High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63(7):1454-7. View

Lim H, Devesa S, Sosa J, Check D, Kitahara C . Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017; 317(13):1338-1348. PMC: 8216772. DOI: 10.1001/jama.2017.2719. View

Jackson S, Kumar G, Banizs A, Toney N, Silverman J, Narick C . Incremental utility of expanded mutation panel when used in combination with microRNA classification in indeterminate thyroid nodules. Diagn Cytopathol. 2019; 48(1):43-52. PMC: 6972518. DOI: 10.1002/dc.24328. View

McIver B, Castro M, Morris J, Bernet V, Smallridge R, Henry M . An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. 2014; 99(11):4069-77. DOI: 10.1210/jc.2013-3584. View

Nikiforov Y, Ohori N, Hodak S, Carty S, LeBeau S, Ferris R . Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011; 96(11):3390-7. PMC: 3205883. DOI: 10.1210/jc.2011-1469. View

10.

Lemoine N, Mayall E, Wyllie F, Farr C, Hughes D, Padua R . Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988; 48(16):4459-63. View

11.

Sistrunk J, Shifrin A, Frager M, Bardales R, Thomas J, Fishman N . Clinical impact of testing for mutations and microRNAs in thyroid nodules. Diagn Cytopathol. 2019; 47(8):758-764. PMC: 6766884. DOI: 10.1002/dc.24190. View

12.

Suarez H, Du Villard J, Caillou B, Schlumberger M, TUBIANA M, Parmentier C . Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene. 1988; 2(4):403-6. View

13.

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

14.

Steward D, Carty S, Sippel R, Yang S, Sosa J, Sipos J . Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. JAMA Oncol. 2018; 5(2):204-212. PMC: 6439562. DOI: 10.1001/jamaoncol.2018.4616. View

15.

Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B . BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95(8):625-7. DOI: 10.1093/jnci/95.8.625. View

16.

Alexander E, Kennedy G, Baloch Z, Cibas E, Chudova D, Diggans J . Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012; 367(8):705-15. DOI: 10.1056/NEJMoa1203208. View

17.

Brauner E, Holmes B, Krane J, Nishino M, Zurakowski D, Hennessey J . Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules. Thyroid. 2015; 25(7):789-96. DOI: 10.1089/thy.2015.0049. View

18.

Patel K, Angell T, Babiarz J, Barth N, Blevins T, Duh Q . Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules. JAMA Surg. 2018; 153(9):817-824. PMC: 6583881. DOI: 10.1001/jamasurg.2018.1153. View

19.

Labourier E, Shifrin A, Busseniers A, Lupo M, Manganelli M, Andruss B . Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology. J Clin Endocrinol Metab. 2015; 100(7):2743-50. PMC: 4490308. DOI: 10.1210/jc.2015-1158. View

20.

Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R . Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013:965212. PMC: 3664492. DOI: 10.1155/2013/965212. View